Pfizer to cut 800 scientists

Pfizer will eliminate 5 to 8 percent of its global research staff this year, totaling about 800 people, according to a spokesperson for the company. Pfizer began one-on-one conversations today with colleagues getting the boot, with the majority of lay-offs happening in the next several months, company spokesperson Christopher Loder told The Scientist. Loder declined to provide details on which research divisions will be hit the hardest but emphasized that Pfizer is honing its research staff to

Written byAndrea Gawrylewski
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Pfizer will eliminate 5 to 8 percent of its global research staff this year, totaling about 800 people, according to a spokesperson for the company. Pfizer began one-on-one conversations today with colleagues getting the boot, with the majority of lay-offs happening in the next several months, company spokesperson Christopher Loder told The Scientist. Loder declined to provide details on which research divisions will be hit the hardest but emphasized that Pfizer is honing its research staff to six major areas of disease research: oncology, Alzheimer's, schizophrenia, pain, diabetes, and inflammation. "We do not make these decisions lightly," he said. "We are aware that this decision will affect a of number people, colleagues, and their family. We are committed to supporting our colleagues through this transition." Pfizer suffered last year from slumping sales of its blockbuster cholesterol drug Lipitor, thanks to the availability of a generic version. "This is probably not the end" of layoffs at Pfizer, linkurl:Erik Gordon,;http://www.bus.umich.edu/FacultyBios/FacultyBio.asp?id=000191546 a professor at the University of Michigan Business School and biopharmaceutical analyst, told linkurl:The New York Times.;http://www.nytimes.com/2009/01/14/business/14pfizer.html?_r=2&hp The pharmaceutical giant is not the only one cutting jobs and reorganizing priorities. Last October Merck announced that it would slash 7,200 jobs by 2011. In addition, Merck and Novartis both have recently revamped their research and development tactics.
**__Related stories:__***linkurl:Merck to cut jobs;http://www.the-scientist.com/blog/display/55103/
[22nd October 2008]*linkurl:New directions for drug discovery;http://www.the-scientist.com/blog/display/55274/
[9th December 2008]*linkurl:Pfizer embraces stem cells;http://www.the-scientist.com/blog/display/55051/
[24th September 2008]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies